Summary & Overview
CPT 0360T: Insertion of Drug-Eluting Implant into Lacrimal Canaliculus
CPT code 0360T represents the insertion of a drug-eluting implant into the lacrimal canaliculus, a minimally invasive ophthalmic procedure that can include punctal dilation and implant removal when performed. The code reflects a growing niche in procedural dry eye and lacrimal drainage disorder management by providing localized, sustained drug delivery directly within the punctal/canalicular system. Nationally, this code matters as payers and providers navigate coverage, appropriate use, and coding alignment for novel implant therapies in eye care. Key payers discussed include Aetna, Cigna Health, UnitedHealthcare, and Medicare. Readers will gain a concise clinical and billing orientation to CPT code 0360T, including the procedure’s clinical context and typical sites of service, related procedural codes for lacrimal interventions, and which diagnoses commonly align with its use. The publication also summarizes benchmark issues and policy considerations relevant to adoption and reimbursement of device-based canalicular therapies. Data not available in the input for some specific payer coverage policies and utilization benchmarks are noted where applicable.
Billing Code Overview
CPT code 0360T describes the insertion of a drug-eluting implant into the lacrimal canaliculus, and includes punctal dilation and implant removal when performed. This procedure is a targeted treatment for disorders of the lacrimal drainage system, most commonly used in managing symptoms related to tear film dysfunction and canalicular obstruction.
Service type: minor ophthalmic implant procedure
Typical site of service: ambulatory surgical center or ophthalmology clinic procedural suite
Clinical & Coding Specifications
Clinical Context
A 62-year-old patient with symptomatic dry eye refractory to topical therapies presents to an ophthalmic plastic surgeon. The patient reports persistent tear film instability and ocular surface irritation with lubrication drops providing inadequate relief. Clinical exam demonstrates punctal stenosis and reduced tear meniscus height; irrigation suggests partial lacrimal outflow obstruction. After shared decision-making, the surgeon performs insertion of a drug-eluting implant into the affected lacrimal canaliculus (0360T) to deliver sustained anti-inflammatory medication. The procedure typically occurs in an ambulatory surgical center or ophthalmologists procedure room under local anesthesia with topical and/or injectable anesthetic. The workflow includes pre-procedure consent and documentation of indications (e.g., H04.121, H04.122, H04.123, H04.129, H04.531, H04.532), punctal dilation as needed, implantation of the drug-eluting device into each treated canaliculus, and implant removal when performed. Post-procedure documentation covers laterality, number of implants, implant removal (if performed), immediate procedural findings, and post-op instructions. Typical sites of service are outpatient ophthalmology clinics, procedure rooms, and ambulatory surgical centers.
Coding Specifications
| Modifier |
|---|